A rare complication after pacemaker implantation: unusually shaped lead coil.

31:184–194. 6. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366–3373. 7. Nurden AT, Nurden P. Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol 2003; 23:158–159. 8. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038–1047. First published on February 13, 2006, doi:10.1093/eurheartj/ehi754. 9. van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195–204. 10. Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140, an oral reversible ADP receptor antagonist. Haematologica 2004;89(Suppl. 7):14.